DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



D-Cycloserine Augmentation of Behavior Therapy for Individuals With Body Dysmorphic Disorder

Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Body Dysmorphic Disorder

Intervention: d-cycloserine (Drug); Placebo (Drug)

Phase: Phase 0

Status: Recruiting

Sponsored by: Massachusetts General Hospital

Official(s) and/or principal investigator(s):
Sabine Wilhelm, PhD, Principal Investigator, Affiliation: Massachusetts General Hospital

Overall contact:
Alexandra Sullivan, BS, Phone: 617-643-4387, Email: adsullivan@mgh.harvard.edu

Summary

The purpose of the study is to conduct a double-blind, placebo-controlled study of D-cycloserine (DCS) augmentation of behavior therapy in individuals with Body Dysmorphic Disorder (BDD). Specifically, we intend to randomize 50 individuals with BDD to receive either DCS (n = 25) or placebo (n = 25) one hour prior to 8 of 10 behavior therapy sessions.

Clinical Details

Official title: A Randomized, Double-blind, Placebo-controlled Trial of D-cycloserine Augmentation of Behavior Therapy for Body Dysmorphic Disorder

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Body Dysmorphic Disorder Yale-Brown Obsessive Compulsive Scale (BDD-YBOCS)

Detailed description: This treatment study also provides us with the opportunity to further explore the molecular genetics of BDD, as well as the genetic predictors of response to an extinction-based treatment. We will take a hypothesis-driven approach by focusing on genes and systems previously shown to mediate fear acquisition and NMDA-dependent extinction learning including NMDA-related glutamatergic loci (GRIN1, GRIN2A, GRIN2B, DAAO, DAOA) and three other genes strongly implicated in fear extinction (BDNF, NTRK2, CNR1). Other loci of interest in the molecular genetics of BDD include: the serotonin transporter gene, dopamine, GABA-A, and cytochrome P450 genes.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- 18 years of age or older

- Primary diagnosis of Body Dysmorphic Disorder as determined by DSM-IV criteria

- BDD Yale-Brown Obsessive Compulsive Scale score greater than or equal to 24

- Females of childbearing potential must have a negative urinary beta-HCG test

- Subjects currently taking psychotropic medication must be on a stable does for at

least two months prior to initiating study procedures Exclusion Criteria:

- Pregnant or breastfeeding women will be excluded

- People taking medications that may interfere with DCS

- History of seizure disorder or other serious medical illnesses such as

cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease

- Comorbid psychiatric diagnoses (alcohol dependence, bipolar disorder, psychosis,

borderline personality disorder, organic mental disorder, or development disorder). If subjects have any other comorbid disorder, the BDD symptoms have to be the primary concern.

- Persons taking medications that may lower seizure threshold, including clozapine,

pethidine, and the following antibiotics in high dosage: penicillins, cephalosporins, amphotericin, and imipenem

- Those deemed to pose a serious suicidal or homicidal threat will be excluded

- Current psychotherapy or failure to benefit from ten or more sessions of previous ERP

treatment is a rule-out

Locations and Contacts

Alexandra Sullivan, BS, Phone: 617-643-4387, Email: adsullivan@mgh.harvard.edu

Massachusetts General Hospital, Boston, Massachusetts 02114, United States; Recruiting
Alexandra Sullivan, BS, Phone: 617-643-3487, Email: adsullivan@mgh.harvard.edu

Massachusetts General Hospital, Boston, Massachusetts 02114, United States; Recruiting
Alexandra Sullivan, BS, Phone: 617-643-4387, Email: adsullivan@mgh.harvard.edu

Additional Information

Mass General Hospital BDD clinic website

OCD and Related Disorders Clinic at MGH

Starting date: November 2008
Last updated: August 14, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017